Summary of Study ST003050

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001899. The data can be accessed directly via it's Project DOI: 10.21228/M88147 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST003050
Study TitlePlasma instead of serum avoids critical confounding of clinical metabolomics studies by platelets (Part 1/3 - Plasma and serum eicosadomics)
Study SummaryMetabolomics is an emerging and powerful molecular profiling method supporting clinical investigations. Serum and plasma are commonly used without rational prioritization. Serum is collected after blood coagulation, a complex biochemical process involving active platelet metabolism. This may affect the metabolome and increase the variance as platelet counts and function may vary substantially in individuals. A multi-omics approach systematically investigating the suitability of serum and plasma for clinical studies demonstrated that metabolites correlated well (n=461, R2=0.991), whereas lipid mediators (n=104, R2=0.906) and proteins (n=322, R2=0.860) differed substantially between specimen. Independently, analysis of platelet releasates identified most biomolecules significantly enriched in serum when compared to plasma. A prospective, randomized, controlled parallel group metabolomics trial with acetylsalicylic acid administered for 7 days demonstrated that the apparent drug effects significantly differ depending on analyzed specimen. Only serum analyses of healthy individuals suggested a significant downregulation of TXB2 and 12-HETE, which were specifically formed during coagulation in vitro. Plasma analyses reliably identified acetylsalicylic acid effects on metabolites and lipids occurring in vivo such as a decrease in polyunsaturated fatty acids. The present data suggests that plasma should be preferred above serum for clinical metabolomics studies as the serum metabolome may be substantially confounded by platelets.
Institute
University of Vienna
DepartmentDepartment of Analytical Chemistry
LaboratoryGerner lab
Last NameHagn
First NameGerhard
AddressWähringerstraße 38, 1090 Vienna, Austria
Emailgerhard.hagn@univie.ac.at
Phone+43 1 4277 52375
Submit Date2024-01-17
Raw Data AvailableYes
Raw Data File Type(s)raw(Thermo)
Analysis Type DetailLC-MS
Release Date2024-04-12
Release Version1
Gerhard Hagn Gerhard Hagn
https://dx.doi.org/10.21228/M88147
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Treatment:

Treatment ID:TR003174
Treatment Summary:Subjects were randomized to receive either acetylsalicylic acid or Omega-3 capsules for 7 days. One study cohort was instructed to take 500 mg acetylsalicylic acid (Aspirin® 500 mg acetylsalicylic acid, Cellulose powder, maize starche) per day in the evening whereas the second study cohort was instructed to take two Omega-3 complex 870 mg capsules (Br. Böhm Omega-3 capsules, 1017 mg cold water fish oil equivalent to 870 mg Omega-3, consisting of 420 mg EPA, 330 mg DHA, 5μg Vitamin D equivalent to 200 IU, 6 mg Vitamin E, 30 mg Co-enzyme Q10) per day in the evening.
  logo